LYN-00101

LYN-00101 is a fully humanized monoclonal antibody that functions as an inhibitor of vascular endothelial growth factor (VEGF). It is designed to block autocrine loops involving VEGF receptors 1, 2, and 3 (VEGFR1/2/3), thereby inhibiting angiogenesis—a process critical for tumor growth and metastasis. The drug was developed by Lynkcell and has been investigated primarily for the treatment of various cancers, including colorectal cancer, ovarian cancer, stomach cancer, cervical cancer, and gastrointestinal cancers. Its mechanism of action is similar to other anti-VEGF therapies such as bevacizumab but represents a distinct investigational agent from Lynkcell[1][2][3].

Other names

Anti-VEGF monoclonal antibody